The following is an update provided by Public Health England on the supply situation for vaccines purchased direct from the manufacturers (e.g. for travel and risk groups); these vaccines are not procured and supplied centrally for national immunisation programmes.
Hepatitis A vaccine
Adult vaccine
- Sanofi Pasteur currently have ordering restrictions in place of 7 doses per month per account for Avaxim.
- GSK are out of stock in some areas for Havrix pre-filled syringe single packs until the beginning of April 2017. Havrix pre-filled syringe packs of 10 are unavailable until 2018.
- MSD are out of stock of VAQTA and estimate that supplies will resume around mid-June.
Paediatric vaccine
- GSK have paediatric doses of Havrix Monodose available.
- MSD are out of stock of VAQTA and estimate that supplies will resume around mid-June.
Hepatitis B vaccine
Adult vaccine
- GSK have Engerix B pre-filled syringe singles and Engerix B vials in stock. Engerix B pre-filled syringe 10 packs are unavailable until 2018.
- GSK have supplies of Fendrix available.
- MSD currently have the HBVAXPRO 40μg preparation in stock. The HBVAXPRO 10μg preparation is currently out of stock, anticipated to be back in stock around early July.
Paediatric vaccine
- GSK have paediatric doses of Engerix B available.
- MSD currently have the HBVAXPRO 5μg preparation in stock.
Hepatitis A and Hepatitis B combined vaccine
Supplies of the adult and paediatric presentation (Twinrix and Ambirix) remain available from GSK.
Hepatitis A and Typhoid combined vaccines
- Sanofi Pasteur are experiencing supply constraints with ViaTIM until late October 2017.
- GSK is out of stock of Hepatyrix until at least 2019.
Rabies vaccine
- GSK currently have vials of Rabipur available and a new presentation of pre-filled syringes and vials should also be available in April.
- Sanofi Pasteur have intermittent supply constraints with the licensed preparation (Rabies Vaccine BP) and customers may wish to discuss obtaining supplies with Sanofi directly.
The supply situation for these vaccines is based on manufacturers’ disclosure to DH and PHE. The supply situation is dynamic and shortages from one supplier combined with increased demand due to outbreaks (e.g. hepatitis A clusters among men who have sex with men (MSM)) may put additional pressures on other manufacturers.
Further information, including advice on prioritising vaccine during shortages, is available in the PHE Vaccine update issue 260, March 2017
